Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting
29 Junio 2023 - 8:00AM
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical
company developing innovative therapeutics to specifically treat
metastatic breast cancers harboring ESR1 mutations, today announced
it will present two posters, addressing sexual and urogenital
health of metastatic breast cancer patients, at The Menopause
Society (formerly North American Menopause Society, or NAMS) 2023
Annual Meeting, to be held Sept. 27-30 at the Downtown Marriott in
Philadelphia.
“Quality of life, which includes sexual and overall
genitourinary health, is a constant concern for the vast majority
of women confronted with metastatic breast cancer,” said Dr. David
Portman, founder and chief executive officer of Sermonix. “Our lead
investigational drug, lasofoxifene, has demonstrated potential
benefit with respect to vaginal and sexual health, and we are
excited to continue investigating this vitally important aspect of
disease management during our upcoming Phase 3 study. We look
forward to engaging with our peers at The Menopause Society 2023
Annual Meeting and sharing our most recent findings.”
Sermonix will share its two posters Thursday, Sept. 28, from
6:15-7:15 p.m. ET. They are:
- “Vaginal and vulvar symptoms in patients with
ESR1-mutated, ER+/HER2- metastatic breast cancer by baseline
characteristics”The objective of this analysis was to
evaluate the effects of patient characteristics on baseline
vaginal/vulvar symptoms in the Phase 2 Evaluation of Lasofoxifene
in ESR1 Mutations (ELAINE-1) study assessing the efficacy and
safety of oral lasofoxifene versus intramuscular fulvestrant.
- “Vaginal and sexual health
in patients with ER+/HER2- metastatic breast cancer
(mBC)”This poster analyzes the results of the 50-question,
online EQUALS 2 (ESR1 QUAlity of Life Survey 2) survey, whose
objective was to better understand vaginal and sexual health
concerns of women with ER+/HER2- metastatic breast cancer.
“The theme of this year’s meeting is ‘Midlife Women’s Health in
the Era of Precision Medicine,’” said Dr. Lisa Larkin,
president-elect of The Menopause Society board of trustees.
“Sermonix’s efforts in the precision medicine women’s oncology
space is significant and its investigation of targeted therapy
lasofoxifene’s impact on vaginal and sexual health is much needed
in an arena that is currently so underserved. We look forward to
Sermonix’s participation in The Menopause Society Annual Meeting
and as a member of our 2023 Corporate Liaison Council.”
Sermonix in March initiated ELAINE-3, a registrational Phase 3
study of 400 patients assessing the efficacy of lasofoxifene and
abemaciclib. Enrollment will begin soon.
To learn more about Sermonix Pharmaceuticals and lasofoxifene,
visit https://sermonixpharma.com. To learn more about the ELAINE
studies, visit https://elainestudy.com/.
About LasofoxifeneLasofoxifene is an
investigational novel endocrine therapy in clinical development
which has demonstrated robust target engagement as an ESR1
antagonist in the breast, particularly in the presence of ESR1
mutations. Lasofoxifene has demonstrated anti-tumor activity as
monotherapy and in combination with a CDK4/6 inhibitor in Phase 2
studies and has unique tissue selectivity distinguishing it from
other current and investigational endocrine therapies, with
beneficial effects seen on vagina and bone in previous clinical
studies. Lasofoxifene, which Sermonix licensed globally from Ligand
Pharmaceuticals Inc. (NASDAQ:LGND), has been studied in previous
comprehensive Phase 1-3 non-oncology clinical trials in more than
15,000 postmenopausal women worldwide. Lasofoxifene’s
bioavailability and activity in mutations of the estrogen receptor
could potentially hold promise for patients who have acquired
endocrine resistance due to ESR1 mutations, a common finding in the
metastatic setting and an area of high unmet medical need.
Lasofoxifene’s novel activity in ESR1 mutations was discovered at
Duke University and Sermonix has exclusive rights to develop and
commercialize the product in this area. Lasofoxifene, a novel
targeted and tissue selective oral endocrine therapy could, if
approved, play a critical role in the precision medicine treatment
of advanced ER+ breast cancer.
About SermonixSermonix Pharmaceuticals Inc. is
a privately held biopharmaceutical company focused on the
development of female-specific oncology products and is currently
undertaking two Phase 2 clinical studies of lasofoxifene, its lead
investigational drug. The Sermonix management team, led by founder
Dr. David Portman, has significant experience in all stages of the
drug development, regulatory and commercialization processes. Paul
Plourde, M.D., vice president of oncology clinical development, has
many decades of experience at AstraZeneca in the breast cancer drug
development arena. Barry Komm, Ph.D., chief scientific officer, is
recognized for his expertise in nuclear receptor biology. Miriam
Portman, M.D., is co-founder and chief operating officer, with
expertise in clinical trial conduct and patient recruitment.
Elizabeth Attias, M.M.Sc., Sc.D., chief strategy and development
officer, has extensive experience in pharmaceutical drug
commercialization. Simon Jenkins, Ph.D., vice president of
operations, has over 30 years of experience in global drug
development leadership. Sermonix non-executive chairman of the
board is Anthony Wild, Ph.D., former president of both Parke-Davis
Pharmaceuticals and Warner-Lambert’s Pharmaceutical Division. Learn
more at SermonixPharma.com.
Sermonix Media Contact:Monica Kozlowski,
MSPHSermonix Product
Managermkozlowski@sermonixpharma.com860-692-8548
Ligand Pharmaceuticals (NASDAQ:LGND)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Gráfica de Acción Histórica
De May 2023 a May 2024